Maintenance Obinutuzumab for Primary Central Nervous System Lymphoma Complete Responders
Phase of Trial: Phase II
Latest Information Update: 19 Jun 2018
At a glance
- Drugs Obinutuzumab (Primary)
- Indications B cell lymphoma; Lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 11 Jun 2018 Planned End Date changed from 1 Apr 2022 to 18 Apr 2021.
- 28 Nov 2016 Status changed from not yet recruiting to recruiting.
- 08 Apr 2016 Planned End Date changed from 1 Sep 2020 to 1 Apr 2022.